Quick Links
Main Menu
More Links

Latest Nursing Jobs &
Clinical Update Alerts!

Subscribe to get timely notifications.

Latest Nursing Jobs Vacancies
NCLEX & CGFNS Practice Questions

Wood’s Light Examination

Wood’s Light Examination

The Wood’s Light Examination is a useful and inexpensive tool in clinical practice. It is powered by alternating or direct current that converts ultraviolet light into visible light, and it usually has an accompanying magnification lens. It provides a simple diagnostic method in the evaluation of
● Many dermatological problems
Fluorescein-staining evaluation of eye injuries



OVERVIEW
● Most common dermatological lesions that fluoresce are listed on the table below.
● Detection of chemicals applied to the skin. Affected areas are a different color from that of the surrounding skin.
● Prior cleansing of the area to be examined causes false-negative result.
● Certain skin lesions do not fluoresce.
● Systemic antibiotic therapy, such as with tetracyclines, can cause fluorescence in some lesions.
● Cosmetics present on the skin interfere with fluorescence.
● Detection of eye injuries with fluorescein. When applied to the eye, fluorescein has a higher concentration of uptake in areas in which there has been disruption of the cornea or sclera. Under a Wood’s light, the injured area fluoresces as a bright yellow-green.
● Detection of porphyrins in the urine. These appear bright red.
CLICK HERE for more resources on Fundamentals of Nursing
CLICK HERE for more resources on Laboratory & Diagnostic Test

Fluorescence of Lesions and Parasites With the Wood’s Light

LESION FLUORESCENCE
Erythrasma
Corynebacterium minutissimum Varying shades of pink to coral red
Tinea Capitis (Three Varieties)
Microsporum audouinii Brilliant green
M. canis Brilliant green
Trichophyton schoenleinii Pale green
Tinea Versicolor Yellow to deep green
Pseudomonas aeruginosa Blue green to green
Pigmentation Alterations
Albinism Cold bright white
Ash-leaf spot of tuberous sclerosis Blue-white
Depigmentation Cold bright white
Hypopigmentation Blue-white
Hyperpigmentation Purple-brown
Leprosy Blue-white
Vitiligo Blue-white
Squamous cell carcinoma* Bright red
Common Parasitic Infestations
Scabies Magnification of track and/or mite
Pediculosis (capitis, corporis, pubis) Visualization of louse

* The diagnosis of this dermatological disorder should be made by pathological assessment.

RATIONALE
● Skin—To allow the clinician to differentiate dermatological presentation of types of bacterial, fungal, and pigmented lesions found on the skin
● Eye—To allow the visual assessment of injuries to the cornea and conjunctiva with fluorescein staining
● Urine—To screen for porphyria—a rare metabolic disorder
● Clinical evaluation of dermatitis, the eye, or urine by the unaided eye alone may result in an inappropriate assessment and render an unsuccessful treatment regimen.



INDICATIONS
● Skin or hair lesions
● Corneal abrasion
● Suspicion of porphyria

CONTRAINDICATIONS
● None

PROCEDURE
Wood’s Light—Skin
Equipment
● Wood’s light
● Darkened room

Procedure
● Have the client position himself or herself comfortably.
● Explain to the client that the Wood’s light has the same characteristics as a typical black light; the room will be darkened, and the black light will be turned on to examine for fluorescence of the lesion in question.
● Have all lights turned off.
● Hold the Wood’s light approximately 6 to 8 inches from the lesion in question, and observe the characteristics of the fluorescence of the lesion.



BIBLIOGRAPHY
Driscoll C, Bope ET. The Family Practice Desk Reference. 4th ed. St. Louis, MO: Mosby; 2002.
Habif T. Clinical Dermatology: A Color Guide to Diagnosis and Therapy. 5th ed. St. Louis, MO: Mosby; 2011.
Murtagh J. Practice Tips. 5th ed. New York, NY: McGraw-Hill; 2008.
Pfenninger JL, Fowler GC. Procedures for Primary Care Physicians. St. Louis, MO: Mosby; 2011.

CLICK HERE for more resources on Fundamentals of Nursing
CLICK HERE for more resources on Laboratory & Diagnostic Test

Nursing Responsibilities during Breast Biopsy

Nursing Responsibilities during Breast Biopsy

Normal Findings
• Breast tissue consisting of cellular and noncellular connective tissue, fat lobules, and various lacti ferous ducts
• Pink appearance with more fatty than fibrous tissue
• Absence of abnormal cell development or tissue elements

Abnormal Findings
• Benign tumors such as in fibrocystic disease, adenofibroma, intraductal papilloma, mammary fat necrosis, and plasma cell mastitis (mammary duct ectasia)
• Malignant tumors such as in adenocarcinoma, cystosarcoma, intraductal carcinoma, infiltrating carcinoma or circumscribed carcinoma, colloid carcinoma, lobular carcinoma, sarcoma, and Paget’s disease

Nursing Implications
• Anticipate the need for additional testing.
• Provide emotional support to the patient during this period.

Purpose
• To differentiate between benign and malignant breast tumors



Description
Breast biopsy is performed to confirm or rule out breast cancer after clinical examination, mammography, or
thermography has identified a mass. Common techniques include fine-needle or needle biopsy (performed when
a patient has a fluid-filled mass that’s been identified by ultrasonography) and open biopsy (performed to allow access to the complete tissue system, which can be sectioned to allow more accurate
evaluation). In some cases, stereotactic breast biopsy may be used. This involves immobilizing the breast and allowing a computer to calculate the exact location of the mass based on x-rays from two angles.
A breast biopsy can usually be done on an outpatient basis under local anesthesia; however, an excisional open
biopsy may require general anesthesia. If sufficient tissue is obtained and the mass is found to be a malignant tumor, specimens are sent for estrogen and progesterone receptor assays to assist in determining future therapy and the prognosis.
The usual procedures for needle and open biopsies are as follows:

Needle Biopsy
• The patient is instructed to undress to the waist, and is placed in a sitting or recumbent position with her arms
at her sides.
• The biopsy site is prepared, a local anesthetic is administered, and the syringe (luer-lock syringe for aspiration, Vim-Silverman needle for tissue specimen) is introduced into the lesion.
• Fluid aspirated from the breast is expelled into a properly labeled, heparinized tube; the tissue specimen is placed in a labeled specimen bottle containing normal saline solution or formalin. With fine needle aspiration, a slide is made for cytology and viewed immediately under a microscope. (Because breast fluid aspiration isn’t considered diagnostically accurate, some practitioners aspirate fluid only from cysts. If such fluid is clear yellow and the mass disappears, the aspiration procedure is diagnostic and therapeutic, and the aspirate is discarded. If aspiration yields no fluid or if the lesion recurs two or three times, an open biopsy is then considered appropriate.)
• Pressure is exerted on the biopsy site and, after bleeding stops, an adhesive bandage is applied.

CLICK HERE for more resources on Laboratory & Diagnostic Test
CLICK HERE for resources on Fundamentals of Nursing

Open Biopsy
• After the patient receives a general or local anesthetic, an incision is made in the breast to expose the
mass.
• The practitioner may then incise a portion of tissue or excise the entire mass. If the mass is smaller
than ¾” (2 cm) in diameter and appears benign, it’s usually excised; if it’s larger or appears malignant, a
specimen is usually incised before the mass is excised. Incisional biopsy generally provides an adequate specimen for histologic analysis.
• The specimen is placed in a properly labeled specimen bottle containing 10% formalin solution. Tissue that appears malignant is sent for frozen section and receptor assays. Receptor assay specimens must not be placed
in the formalin solution.
• The wound is sutured and an adhesive bandage applied.
Because breast cancer remains the most prevalent cancer in women, genetic researchers are continually working to identify women at risk.




Interfering Factors
• Failure to obtain an adequate tissue specimen
• Failure to place the specimen in the proper solution

Precautions
• Breast biopsy is contraindicated in the patient with a condition that precludes surgery.

Nursing Considerations(Responsibilities)
Before the Test
• Confirm the patient’s identity using two patient identifiers according to facility policy.
• Describe the procedure to the patient, and explain that breast biopsy permits microscopic examination of a breast tissue specimen. Offer her emotional support, and assure her that breast masses don’t always indicate cancer.
• Inform the patient scheduled for a needle biopsy that she’ll need to sit still during the procedure.
• If the patient is to receive a local anesthetic, advise her that she doesn’t need to restrict food, fluids, and medication. If she’s to receive a general anesthetic, advise her to fast from midnight before the procedure until after the biopsy.
• Tell the patient who will perform the biopsy, and where and when it will be done. Explain that pretest studies, such as blood tests, urine tests, and chest X-rays, may be required.
• Make sure the patient or a responsible family member has signed an informed consent form.
• Check the patient’s history for hypersensitivity to anesthetics.

CLICK HERE for more resources on Laboratory & Diagnostic Test
CLICK HERE for resources on Fundamentals of Nursing

During the Test
• Remind the patient undergoing a needle biopsy to sit still.
• Assist with the collection of specimens into the appropriate containers,if indicated.
• Send the specimens to the laboratory immediately, if appropriate.



After the Test
• If the patient has received a general or local anesthetic, monitor the patient’s vital signs regularly. If she
has received a general anesthetic, check her vital signs every 15 minutes for 1 hour, every 30 minutes for 2 hours, every hour for the next 4 hours, and then every 4 hours.
• Administer analgesics for pain, as ordered, and provide ice bags for comfort.
• Instruct the patient to wear a support bra at all times until healing is complete.
• Observe for and report bleeding, tenderness, and redness at the biopsy site.
• Provide emotional support to the patient awaiting diagnosis.

Managing an Obstructed Airway (Heimlich Maneuver)

Abdominal thrusts (also called the Heimlich maneuver) is a first aid procedure used to treat upper airway obstructions (or choking) by foreign objects. The term Heimlich maneuver is named after Dr. Henry Heimlich, who first described it in 1974.

Goal: Remove a foreign body from obstructing the airway to prevent anoxia and cardiopulmonary arrest.

Conscious Child or Adult (Heimlich Maneuver)
1. The patient will be standing or sitting. Stand behind the patient. Wrap your arms around patient’s waist. Make a
fist with one hand. Place thumb side of fist against patient’s abdomen, above the navel but below the xiphoid process.
2. Grasp fist with other hand. Press fist into abdomen with a quick upward thrust.
3. Repeat distinct separate thrusts until the patient expels the foreign body or becomes unconscious.
CLICK HERE for more resources on Fundamentals of Nursing



Unconscious Patient (Heimlich Maneuver, Abdominal Thrust)
1. Patient will be lying on the ground. Turn patient on back and call for help. Activate emergency response system.
2. Finger sweep:
a. Use tongue–jaw lift to open mouth.
b. Insert index finger inside cheek and sweep to base of tongue if an object is visible. Use a hooking motion, if possible, to dislodge and remove the foreign body. (Note: Avoid finger sweeps in infants and children because you can easily push the foreign body further into the airway. Remove only if clearly visible and easy to reach.)
c. If there is no effective breathing, attempt to provide two rescue breaths. If unsuccessful, reposition and try to ventilate again.
3. Straddle patient’s thighs or kneel to the side of thighs. Place heel of one hand on epigastric area, midline above the navel but below the xiphoid process. Place second hand on top of first hand.
4. Press heel of hand into abdomen with a quick upward thrust. (Note: Be careful to thrust in the midline to prevent injury to the liver or spleen.)
5. Repeat abdominal thrusts five times. If airway is still obstructed, attempt to ventilate using mouth-to-mouth respiration and head tilt/chin lift. Repeat steps 5 through 8 until successful.
CLICK HERE for resources on Nursing Procedure
Children Younger Than 1 Year of Age (Back Blows and Chest Thrusts)
1. Straddle infant over your arm with head lower than trunk.
2. Support head by holding jaw firmly in your hand.
3. Rest your forearm on your thigh and deliver five back blows with the heel of your hand between the infant’s scapula.
4. Place free hand on infant’s back and support neck while turning to supine position.
5. Place two fingers over sternum in same location as for external chest compression (one finger width below nipple line).
6. Administer five chest thrusts.
7. Repeat steps 1 through 6 until airway is not obstructed.



Children Older Than 1 Year of Age
1. Perform Heimlich maneuver with child standing, sitting, or lying as for adult, but more gently.
2. You may need to kneel behind child or have child stand ona table.
3. Prevent foreign body airway obstruction in infants and children by teaching parents or caregivers to do the following:
a. Restrict children from walking, running, or playing with food or foreign objects in their mouths.
b. Keep small objects (e.g., marbles, beads, beans, thumb tacks) away from children younger than 3 years of age.
c. Avoid feeding popcorn and peanuts to children younger than 3 years of age, and cut other foods into small pieces.
4. Instruct parents and caregivers in the management of foreign body airway obstruction.

Pregnant Women or Very Obese Adults (Chest Thrusts)
1. Stand behind patient.
2. Bring your arms under patient’s armpits and around chest.
3. Make a fist and place thumb side against middle of sternum.
4. Grasp fist with other hand and deliver a quick backward thrust.
5. Repeat thrusts until airway is cleared.
6. Chest thrusts may be performed with patient supine and hands positioned with heel over lower half of sternum (as for cardiac compression). Administer separate downward thrusts until airway is clear.
7. Document procedure.

CLICK HERE for more resources on Fundamentals of Nursing
CLICK HERE for resources on Nursing Procedure




Antipsychotics associated with increased risk of pneumonia

Antipsychotics associated with increased risk of pneumonia

By Debbie Andalo

Use of antipsychotic drugs is associated with a higher risk of pneumonia in patients of all ages with or without Alzheimer’s disease, study finds.

The use of antipsychotic drugs in patients with Alzheimer’s disease (AD) doubles their risk of pneumonia, while pneumonia risk in patients without AD who take antipsychotics is more than three-fold, according to research from Finland.

The researchers, who report their findings in Chest, warn that the real risk of pneumonia may be even higher because their study only included cases of pneumonia that led to a hospital stay or patient death.

“Risk-benefit balance should be considered when antipsychotics are prescribed,” the researchers recommend. “Especially old persons who initiate antipsychotic treatment should be closely monitored.”



The team concludes that antipsychotic use is linked to higher pneumonia risk regardless of age, duration of treatment, choice of medication or comorbidities.

CLICK HERE for more resources on Psychiatric/Mental Health

The observational study included 60,584 patients diagnosed with AD who were aged on average 80.1 years and of whom 65.2% were women.

The researchers examined patients’ use of antipsychotics and whether they had a diagnosis of pneumonia that led to hospital admission or death, comparing them with a similar group of patients who did not have AD but were also prescribed antipsychotics.

They found that antipsychotic use was associated with increased pneumonia risk in both groups of patients. There was no difference in risk linked to which antipsychotic was prescribed.

In the AD cohort, antipsychotic users had two-fold relative risk of pneumonia (adjusted hazard ratio [HR] 2.01, 95% confidence interval [CI] 1.90-2.13).

The association was stronger in the non-AD cohort (adjusted HR 3.43, CI 2.99-3.93). In both cohorts, antipsychotic use was consistently associated with higher risk of pneumonia in all age groups.

When the pneumonia risk among users was compared with treatment duration, patients with the shortest duration of use had the highest relative risk increase; the risk was not attenuated in long-term use.



The age-adjusted pneumonia incidence in non-users of AD cohort was 4.83 per 100 person years. The incidence was 13.66 pneumonias per 100 person years in patients who had taken antipsychotics for 7–12 months and 5.30 pneumonias per 100 person years in patients who had taken them for more than one year.

Derek Taylor, chair of the United Kingdom Clinical Pharmacy Association’s Care of the Elderly Group, says: “The results of this study reinforce the existing concern over an increased risk of pneumonia in all patients prescribed an antipsychotic agent.”

Taylor, assistant director of pharmacy in governance & risk at the Royal Liverpool & Broadgreen University Hospitals NHS Trust, says the results of the study suggest that the increased risk of pneumonia appears soon after starting antipsychotic therapy and does not seem to decrease significantly with time in longer-term treatment.

“This would indicate that clinicians should be aware of this increased risk throughout a persons’ antipsychotic treatment course,” he says.

“I do not believe that the results of this study will dramatically alter the prescribing or choice of antipsychotics in patients with AD. However, it does reinforce the need for regular monitoring of patients on both short and longer-term treatment.”

References:

Tolppanen A-M, Koponen M, Tanskanen A et al. Antipsychotic use and risk of hospitalisation or death due to pneumonia in persons with and without Alzheimer’s disease. Chest 2016. doi: 10.1016/j.chest.2016.06.004

Citation: The Pharmaceutical Journal, PJ September 2016 online, online | DOI: 10.1211/PJ.2016.20201657

CLICK HERE for more resources on Psychiatric/Mental Health

WHO Zika Virus Fact Sheet

WHO Zika Virus Fact Sheet

Key facts

• Zika virus disease is caused by a virus transmitted primarily by Aedes mosquitoes.
• People with Zika virus disease can have symptoms including mild fever, skin rash, conjunctivitis, muscle and joint pain, malaise or headache. These symptoms normally last for 2-7 days.
• There is scientific consensus that Zika virus is a cause of microcephaly and Guillain-Barré syndrome. Links to other neurological complications are also being investigated.

Introduction

Zika virus is a mosquito-borne flavivirus that was first identified in Uganda in 1947 in monkeys through a network that monitored yellow fever. It was later identified in humans in 1952 in Uganda and the United Republic of Tanzania. Outbreaks of Zika virus disease have been recorded in Africa, the Americas, Asia and the Pacific. From the 1960s to 1980s, human infections were found across Africa and Asia, typically accompanied by mild illness. The first large outbreak of disease caused by Zika infection was reported from the Island of Yap (Federated States of Micronesia) in 2007. In July 2015 Brazil reported an association between Zika virus infection and Guillain-Barré syndrome. In October 2015 Brazil reported an association between Zika virus infection and microcephaly.

More on the history of Zika virus
Read the latest situation report

Signs and Symptoms

The incubation period (the time from exposure to symptoms) of Zika virus disease is not clear, but is likely to be a few days. The symptoms are similar to other arbovirus infections such as dengue, and include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. These symptoms are usually mild and last for 2-7 days.



Complications of Zika virus disease

After a comprehensive review of evidence, there is scientific consensus that Zika virus is a cause of microcephaly and Guillain-Barré syndrome. Intense efforts are continuing to investigate the link between Zika virus and a range of neurological disorders, within a rigorous research framework.

Q&A: Zika virus and complication

Transmission

Zika virus is primarily transmitted to people through the bite of an infected mosquito from the Aedes genus, mainly Aedes aegypti in tropical regions. Aedes mosquitoes usually bite during the day, peaking during early morning and late afternoon/evening. This is the same mosquito that transmits dengue, chikungunya and yellow fever. Sexual transmission of Zika virus is also possible. Other modes of transmission such as blood transfusion are being investigated.



Diagnosis

Infection with Zika virus may be suspected based on symptoms and recent history of travel (e.g. residence in or travel to an area with active Zika virus transmission). A diagnosis of Zika virus infection can only be confirmed through laboratory tests on blood or other body fluids, such as urine, saliva or semen.

Laboratory testing for Zika virus infection

Treatment

Zika virus disease is usually mild and requires no specific treatment. People sick with Zika virus should get plenty of rest, drink enough fluids, and treat pain and fever with common medicines. If symptoms worsen, they should seek medical care and advice. There is currently no vaccine available.

Prevention

Mosquito bites
Protection against mosquito bites is a key measure to prevent Zika virus infection. This can be done by wearing clothes (preferably light-coloured) that cover as much of the body as possible; using physical barriers such as window screens or closing doors and windows; sleeping under mosquito nets; and using insect repellent containing DEET, IR3535 or icaridin according to the product label instructions. Special attention and help should be given to those who may not be able to protect themselves adequately, such as young children, the sick or elderly. Travellers and those living in affected areas should take the basic precautions described above to protect themselves from mosquito bites.

It is important to cover, empty or clean potential mosquito breeding sites in and around houses such as buckets, drums, pots, gutters, and used tyres. Communities should support local government efforts to reduce mosquitoes in their locality. Health authorities may also advise that spraying of insecticides be carried out.

Vector control operations framework for Zika virus



Sexual transmission
Sexual transmission of Zika virus has been documented in several different countries. To reduce the risk of sexual transmission and potential pregnancy complications related to Zika virus infection, the sexual partners of pregnant women, living in or returning from areas where local transmission of Zika virus occurs should practice safer sex (including using condoms) or abstain from sexual activity throughout the pregnancy.

People living in areas where local transmission of Zika virus occurs should also practice safer sex or abstain from sexual activity. In addition, people returning from areas where local transmission of Zika virus occurs should adopt safer sexual practices or abstain from sex for at least 8 weeks after their return, even if they don’t have symptoms. If men experience Zika virus symptoms they should adopt safer sexual practices or consider abstinence for at least 6 months. Those planning a pregnancy should wait at least 8 weeks before trying to conceive if no symptoms of Zika virus infection appear, or 6 months if one or both members of the couple are symptomatic.

Prevention of sexual transmission of Zika virus



WHO response

WHO is supporting countries to control Zika virus disease by taking actions outlined in the “Zika Strategic Response Framework”:

• Define and prioritize research into Zika virus disease by convening experts and partners.
• Enhance surveillance of Zika virus and potential complications.
• Strengthen capacity in risk communication to engage communities to better understand risks associated with Zika virus.
• Strengthen the capacity of laboratories to detect the virus.
• Support health authorities to implement vector control strategies aimed at reducing Aedes mosquito populations.
• Prepare recommendations for the clinical care and follow-up of people with complications related to Zika virus infection, in collaboration with experts and other health agencies.

Zika Strategic Response Framework

Guillain-Barré Syndrome Fact Sheet

Guillain-Barré Syndrome

Key facts

• Guillain-Barré syndrome is a rare condition in which a person’s immune system attacks their peripheral nerves.
• People of all ages can be affected, but it is more common in adults and in males.
• Most people recover fully from even the most severe cases of Guillain-Barré syndrome.
• Severe cases of Guillain-Barré syndrome are rare, but can result in near-total paralysis.
• People with Guillain-Barré syndrome should be treated and monitored; some may need intensive care. Treatment includes supportive care and some immunological therapies.

Introduction

In Guillain-Barré syndrome, the body’s immune system attacks part of the peripheral nervous system. The syndrome can affect the nerves that control muscle movement as well as those that transmit feelings of pain, temperature and touch. This can result in muscle weakness and loss of sensation in the legs and/or arms.

It is a rare condition, but people of all ages can be affected, however it is more common in adults and in males. Even in the best of settings, 3%-5% of GBS patients die from complications, which can include paralysis of the muscles that control breathing, blood infection, lung clots or cardiac arrest.



Symptoms

Symptoms typically last a few weeks, with most individuals recovering without long-term, severe neurological complications.

• The first symptoms of Guillain-Barré syndrome include weakness or tingling sensations. They usually start in the legs, and can spread to the arms and face.
• For some people, these symptoms can lead to paralysis of the legs, arms, or muscles in the face. In 20%-25%1of people, the chest muscles are affected, making it hard to breathe.
• Severe cases of Guillain-Barré syndrome are rare, but can result in near-total paralysis. These cases are considered life-threatening, and affected individuals are typically treated in intensive-care units.
• Most people recover fully from even the most severe cases of Guillain-Barré syndrome, although some continue to experience weakness.
CLICK HERE for more resources on neurology

Causes

The cause of Guillain-Barré cannot always be determined, but it is often triggered by an infection (such as HIV, dengue, or influenza) and less commonly by immunization, surgery, or trauma.



Diagnosis

Diagnosis is based on symptoms, findings on neurological examination including diminished or loss of deep-tendon reflexes and lumbar puncture. Other tests, such as blood tests, may be required identify the cause of trigger of GBS.

Researchers are studying a potential – but unproven – link between the surge in GBS cases and Zika virus infection.

Treatment and care

• GBS patients are usually hospitalized so that they can be monitored closely.
• There is no known cure for GBS. But treatments can help improve symptoms of GBS and shorten its duration.
• Supportive care includes monitoring of breathing, heartbeat and blood pressure. In cases where a patient’s ability to breathe is impaired, he or she is usually put on a ventilator and monitored for complications, which can include abnormal heart beat, infections, blood clots, and high or low blood pressure.
• Given the autoimmune nature of the disease, its acute phase is typically treated with immunotherapy, such as plasma exchange to remove antibodies from the blood or intravenous immunoglobulin. It is most often beneficial when initiated 7 to 14 days after symptoms appear.
• In cases where muscle weakness persists after the acute phase of the illness, patients may require rehabilitation services to strengthen their muscles and restore movement.

CLICK HERE for more resources on neurology

Reference
Guillain–Barré Syndrome
Nobuhiro Yuki, M.D., Ph.D., and Hans-Peter Hartung, M.D N Engl J Med 2012.

EMA recommends combination therapies for chronic hepatitis C virus

EMA recommends combination therapies for chronic hepatitis C virus

Sofosbuvir/velpatasvir and grazoprevir/elbasvir found to offer choice and better targeting of genotypes.

Two new combination therapies that have the potential to cure patients with long-term hepatitis C virus (HCV) infection and rule out the need for interferon are being recommended for approval across the EU.

The European Medicines Agency (EMA), which evaluates medicinal products for use in EU, is proposing that marketing authorisation is given to sofosbuvir/velpatasvir (Epclusa; Gilead Sciences) and grazoprevir/elbasvir (Zepatier; Merck Sharp & Dohme).

Both products are direct-acting antivirals, which block the action of proteins that are essential for viral replication. Treatment with them also means that patients do not need to take interferons, which are traditionally poorly tolerated and have serious side effects.



The sofosbuvir/velpatasvir combination targets the proteins NS5B and NS5A, as well as all six genotypes of HCV, while grazoprevir/elbasvir targets the proteins NS3/4A and NS5A and genotypes 1 and 4.

The recommendations follow the results of clinical trials involving patients whose hepatitis C status was tested 12 weeks after taking the combination therapies.

For patients taking sofosbuvir/velpatasvir, researchers found that HCV was no longer detected in the blood 12 weeks after the end of treatment, with or without ribavirin. More than 90% of patients across all genotypes had no detectable HCV in their blood at the end of the trial, and could be considered as ‘cured’ of the virus. The sustained virologic response rate for patients with genotype 3 was around 90%.

More than 90% of patients given grazoprevir/elbasvir had no detectable hepatitis C virus in their blood at 12 weeks. The therapy was particularly effective in patients with chronic kidney disease who usually have a poor prognosis.

The recommendations by the EMA’s Committee for Medicinal Products for Human Use (CHMP) will now go the European Commission for marketing authorisation to be approved.

Sofosbuvir is already available in the EU under the brand name Sovaldi, and as a combination therapy with ledipasvir (Harvoni).

“The major step forward is [sofosbuvir/velpatasvir], which means that there is now a good treatment for genotype 3 hepatitis C,” says Steve Ryder, a consultant physician in hepatology and gastroenterology at the Faculty of Medicine and Health Sciences at the University of Nottingham.

“Almost half of UK patients have this strain and it didn’t respond well to the previous generation of oral treatments… so this is very good news for a group of patients who currently still have to take interferon-based treatments.”

He says grazoprevir/elbasvir is a good combination for genotypes 1 and 4, but adds that there are already “very effective treatments for these genotypes so its main benefit is to potentially provide more choice and drive down the very high cost of these medicines”.

Ryder says the cost of the drugs will affect whether or not they will become available on the NHS.

“NHS England has placed great restrictions on access to Harvoni,” he says. “Many other nations have done much more intelligent deals with pharma that both protect the drug budget but give much better access to treatment than we have [in the UK] – Australia and Israel are good examples.”



The CHMP’s recommendations were welcomed by the charity Hepatitis C Trust. Its chief executive, Charles Gore, says: “More drugs mean more competition, which generally means lower prices. At the same time these drugs work for all genotypes so we should be able to consign the use of interferon to history, even for genotypes 2,3, 5 and 6, which will be a huge benefit and an enormous relief to people living with hepatitis C.”

In May 2016, the World Health Organization published the first ever global viral hepatitis strategy, which sets a worldwide target to eliminate viral hepatitis B and C by 2030. The strategy was unanimously supported by the 194 member states of the World Health Assembly at a meeting on 23–26 May 2016.

Citation: The Pharmaceutical Journal, PJ May 2016 online, online | DOI: 10.1211/PJ.2016.20201234

CLICK HERE for more resources on Gastrointestinal Care

FDA issues warning over loperamide heart risks

FDA issues warning over loperamide heart risks

The US Food and Drug Administration (FDA) has issued a warning that high doses of the antidiarrheal medication loperamide are associated with a risk of heart problems.

The FDA says that healthcare professionals should be aware that higher-than-recommended doses can cause serious cardiac events, including QT interval prolongation, Torsades de Pointes or other ventricular arrhythmias, syncope and cardiac arrest. It also encourages them to consider loperamide, also known by the brand name Imodium, as a possible cause of unexplained cardiac events.

Additionally, the US medicines regulator warns that the risk of serious heart problems can be increased by interactions between loperamide and other drugs, such as some antibiotics and antifungals.



A recent article in the Annals of Emergency Medicine[1] (online, 29 April 2016) highlighted a growing issue of loperamide abuse by people with opioid addiction. The drug, an opioid agonist, has no central nervous system effects at therapeutic doses, but at higher doses might induce euphoria.

The paper outlined two cases where patients had died after using supratherapeutic doses of the drug to manage symptoms of opioid withdrawal. Some people also use loperamide to attempt to self-treat opioid addiction, the authors say.

The FDA says that most reported cases of serious heart problems with loperamide involved doses much higher than the recommended dose. It advises healthcare professionals to counsel patients on the importance of taking only the recommended dose and the risk of cardiac adverse events, as well as potential drug interactions.

Loperamide has been authorised for use in the UK since 1975.



A spokesperson for the Medicines and Healthcare products Regulatory Agency, the UK medicines regulator, says: “We are aware of the safety warning issued by the FDA about the abuse and misuse of loperamide (Imodium). We will consider what implications this may have for UK public health.”

References:

[1]Eggleston W, Clark KH & Marraffa JM. Loperamide abuse associated with cardiac dysrhythmia and death. Annals of Emergency Medicine 2016. doi: 10.1016/j.annemergmed.2016.03.047

Citation: The Pharmaceutical Journal, Vol 296, No 7890, online | DOI: 10.1211/PJ.2016.20201302

STRONG INTER AND INTRA PROFESSIONALISM

STRONG INTER AND INTRA PROFESSIONALISM

INTRODUCTION:
Establishing a professional role is a prerequisite for establishing control over practice in the domain of nursing which includes clinical care, research, education, policy and administration.

Professionalism is having a high standard of skill, knowledge, good judgement and polite behaviour that is expected of a practicing nurse who has been trained to be efficient in her job. Abraham Flexner identified several characteristics related to professionalism, which are: knowledge, specialization, intellectual and individual responsibility and well-developed group consciousness. Authors from various fields have since provided different perspectives on what professionalism means, including knowledge based on scientific principles, accountability, autonomy, inquiry, collegiality, collaboration, innovation inclined with ethics and values.

Nursing and health care practices intersect in interdisciplinary spaces. Inter-professionalism is being intentionally extended through health care in response to economic, human resource and patient safety conditions needing to be addressed. As such, health care providers engage in teams (e.g. Nurses, doctors, Pharmacists, Physiotherapist, Pathologist, Radiologists, Vocational therapists, Dietitians, prosthetists, orthotists etc.)
Health care team’s work and processes are essential components to consider in exploring relationships of individuals brought together inter-professionally to form a team. However, the roles of each team members are at times obscured through layers of power, expectations, stereotypes, trust, understanding, personalities and multitude of other factors that contribute to the complicated nature of health care interactions.



This complicated nature of health care interaction is unfortunately worse intra-professionaly. Interdisciplinary team a group of health care professionals from diverse fields who work in a coordinated fashion toward a common goal for the patient. Example of such group in developed countries are RN (inpatient, ambulatory, etc.)and Advanced Practice Nurses (Clinical Nurse Specialists, Adult/ Child Nurse Practitioners and Primary Nurse Practitioners etc.)
Example of such group in developing countries like Nigeria are RN- orthopaedics, midwifery, accident and emergency, ophthalmic etc (in various specialties with cumulation not amounting to BNSC) , BNSc, MSc Nursing and Phd. (Evaluation of Nigerian Nursing Programmes, and Certification is a presentation for another day).

Intra-professional relations are important topics both for nurses and nursing as we face the ongoing challenges of nurse shortages. Poor colleague relationships, together with workplace conflict, amongst others cause job dissatisfaction. As a consequence, some nurses leave the profession while others continue working but remain chronically unhappy.

Health care environments have become a challenge in recent years due to constant restructuring in an effort to achieve greater efficiency and productivity. These environments have been characterized by rapid change and influences in human resource strategies such as the movement toward flexible workforces.
As medical advances increases, technological advances in patient care have lead to increase demand for more medical procedures and providers who can perform them. Hence, the demand for knowledgeable healthcare practitioners to continue to grow.

Changes have been evident across all settings, making it a chaotic and occasionally unstable work environment. Recognizing that it is sometimes difficult to maintain professionalism in a changing health care setting.
Considering the expected ability of a nurse to BALANCE the following:
• quality and time in COMPLIANCE
• efficiency and effectiveness in CHARACTER
• co-workers’ and clients’ satisfaction/comfort with JOB DESCRIPTION
• Personal and organizational COMMITMENT
• COGNIZANCE based on experience,
• What you say and what they understand in EFFECTIVE COMMUNICATION
• what you see, hear, observe and what you are expected to write in DOCUMENTATION and
• favourable or adverse productivity output of nursing care rendered,
The speaker wonders…….……………………
Has the influence of inter-professionalism swayed nursing, or can the profession and discipline of nursing alter the world of health care inter-professionalism?



Here are recommendations of strong professionalism

1. Knowledge = Seek knowledge that is theoretical, practical and clinical. Being able to apply that knowledge. Using theoretical and/or evidence-based rationale for practice. Synthesizing information from a variety of sources. Using information or evidence from nursing and other disciplines to inform practice. Sharing or communicating knowledge with colleagues, clients, family and others to continually improve care and health outcomes.

2. Spirit of Inquiry = Being open-minded and having the desire to explore new knowledge. Asking questions leading to the generation of knowledge and refinement of existing knowledge. Striving to define patterns of responses from clients, stakeholders and their context. Being committed to life-long learning.

3. Accountability = Understanding the meaning of self-regulation and its implications for practice. Using legislation, standards of practice and a code of ethics to clarify one’s scope of practice. Being committed to work with clients and families to achieve desired outcomes. Being actively engaged in advancing the quality of care. Recognizing personal capabilities, knowledge base and areas for development

4. Autonomy = Working independently and exercising decision-making within one’s appropriate scope of practice. Recognizing relational autonomy and the effects of the context and relationships on this autonomy. Becoming aware of barriers and constraints that may interfere with one’s autonomy and seeking ways to remedy the situation.

5. Inquiry = Understanding the client’s perspective. Assisting the client with their learning needs. Being involved in professional practice initiatives and activities to enhance health care. Being knowledgeable about policies that impact on delivery of health care.




6. Innovation = Visionary concept. Fostering a culture of innovation to enhance client/family outcomes. Showing initiative for new ideas and being involved through taking action. Influencing the future of nursing, delivery of health care and the health care system. Collegiality.

7. Collaboration = Developing collaborative partnerships within a professional context. Acting as a mentor to nurses, nursing students and colleagues to enhance and support professional growth. Acknowledging and recognizing interdependence between care providers.

8. Ethics and Values = Knowledgeable about ethical values, concepts and decision-making. Being able to identify ethical concerns, issues and dilemmas. Applying knowledge of nursing ethics to make decisions and to act on decisions. Being able to collect and use information from various sources for ethical decision-making. Collaborating with colleagues to develop and maintain a practice environment that supports nurses and respects their ethical and professional responsibilities. Engaging in critical thinking about ethical issues in clinical and professional practice.

Mrs ARUNGWA O. T.
29052016

CLICK HERE for more articles from ARUNGWA

New Guidelines Released for Postoperative Pain Management

New Guidelines Released for Postoperative Pain Management

News Author: Pauline Anderson
CME Author: Laurie Barclay, MD

CLINICAL CONTEXT
Acute postoperative pain is common, occurring in more than 80% of patients, with approximately 75% of these having moderate, severe, or extreme pain. Postoperative pain relief is inadequate in more than half of patients, which can negatively affect quality of life, function, and functional recovery, as well as increasing the risks for postsurgical complications and persistent postsurgical pain.

The American Pain Society (APS), in collaboration with the American Society of Anesthesiologists, commissioned an evidence-based guideline on postoperative pain management to promote effective and safer postoperative pain management in children and adults. Topics include preoperative education, perioperative pain management planning, use of different pharmacologic and nonpharmacologic modalities, organizational policies and procedures, and transition to outpatient care.

SYNOPSIS AND PERSPECTIVE
The APS has released a new evidence-based clinical practice guideline that includes 32 recommendations related to postoperative pain management in children and adults.

The guideline is based on the findings of an interdisciplinary expert panel. The APS commissioned the panel with input from the American Society of Anesthesiologists, and the document was subsequently approved by the American Society of Regional Anesthesia and Pain Management.

Research shows that most surgical patients receive inadequate pain relief, which can increase the risks for prolonged postoperative pain, mood disorders, and physical impairment, said lead author Roger Chou, MD, Departments of Medicine and Medical Informatics and Clinical Epidemiology, Oregon Health and Science University, Pacific Northwest Evidence Based Practice Center, Portland.

A key recommendation in the guideline, published in the February issue of the Journal of Pain, is wider use of multimodal techniques, Dr Chou told Medscape Medical News.

“This means using different medications, for example opioids and nonopioid therapies such as non-steroidal anti-inflammatories (NSAIDs), gabapentin/pregabalin, ketamine, lidocaine, administered in different ways, for example, systemically or via neuraxial/peripheral regional anesthetic techniques, as well as medications and nonpharmacological therapies.”

Multimodal strategies help achieve better pain relief while using lower doses of opioids and potentially fewer adverse effects, by affecting pain via different mechanisms of actions and pathways, added Dr Chou.

The recommendation on individualizing therapy is also critical, said Dr Chou. “The same strategy is not going to be ideal in all patients. For example, in patients who are already on long-term opioid therapy prior to surgery, managing their pain is not going to be the same as someone not on opioids.”

The guideline was developed by a 23-member expert panel representing anesthesia, pain management, surgery, nursing, and other medical specialties. It is based on the panel’s review of more than 6500 scientific abstracts and primary studies.

The panel rated each recommendation as strong, moderate, or weak and based each on the quality of the scientific evidence. Of the 32 recommendations, the panel rated only 4 as supported by high-quality evidence, and 11 recommendations were based on low-quality evidence. The guideline authors noted that there were “numerous research gaps.”



In addition to using multimodal therapies, the 3 other strong recommendations with high-quality evidence included the following:

• Using acetaminophen and/or NSAIDs as part of multimodal analgesia for management of postoperative pain in adults and children without contraindications;

• Considering surgical site-specific peripheral regional anesthetic techniques in adults and children for procedures with evidence indicating efficacy; and

• Offering neuraxial analgesia for major thoracic and abdominal procedures, particularly in patients at risk for cardiac complications or prolonged ileus.

Strong recommendations with moderate-quality evidence included the following:

• Administering oral vs intravenous (IV) opioids in patients who can use the oral route;

• Avoiding the intramuscular route for administration of analgesic;

• Choosing IV patient-controlled analgesia (PCA) when the parenteral route is needed;

• Not using routine basal infusion of opioids with IV PCA in opioid-naive adults;

• Considering a preoperative dose of oral celecoxib in adults without contraindications;

• Considering gabapentin or pregabalin as a component of multimodal analgesia;

• Using topical local analgesics in combination with nerve blocks before circumcision;

• Avoiding intrapleural analgesia with local anesthetics for pain control after thoracic surgery;

• Using continuous, local anesthetic-based peripheral regional analgesic techniques when the need for analgesia is likely to exceed the duration of effect of a single injection; and

• Avoiding the neuraxial administration of magnesium, benzodiazepines, neostigmine, tramadol, and ketamine.

Despite low-quality evidence, the panel strongly recommended that clinicians carry out the following strategies:

• Provide patients with education, including information on treatment options;

• Conduct a preoperative evaluation, including assessment of medical and psychiatric comorbidities, concomitant medications, history of chronic pain, and substance abuse;

• Adjust the pain management plan on the basis of adequacy of pain relief and presence of adverse events;

• Use a validated pain assessment tool to track response to postoperative pain treatments and adjust treatment plans accordingly;

• Appropriately monitor sedation, respiratory status, and other adverse events in patients who receive systemic opioids; and

• Provide appropriate monitoring of patients who have received neuraxial interventions for perioperative analgesia.

For cognitive behavioral therapy, the panel had a “weak” recommendation based on moderate-quality evidence to consider this technique as part of a multimodal approach.

The panel found that there was insufficient evidence to recommend or discourage acupuncture, massage, or cold therapy as adjuncts to other postoperative pain treatments. For transcutaneous electrical nerve stimulation, the panel had a “weak” recommendation that clinicians consider this treatment.

As evidence increases on newer techniques for managing postoperative pain, it is important to incorporate these techniques into current practice to improve management of postoperative pain, said Dr Chou. He noted that the APS has not previously issued guidelines on management of postoperative pain and recognizes that this as an important area where evidence-based guidelines could help improve clinical practice.

Dr Chou has disclosed no relevant financial relationships.

J Pain. 2016;17:131-157.[1]



GUIDELINE HIGHLIGHTS
• Currently many preoperative, intraoperative, and postoperative interventions and management strategies are available to reduce and manage postoperative pain.

• Optimal management begins preoperatively with patient evaluation and development of a plan of care specific to each patient and procedure.

• Evidence supports multimodal treatment in many situations, using a variety of analgesic medications and techniques combined with nonpharmacologic interventions, for their synergistic effects and more effective pain relief (strong recommendation; high-quality evidence).

• In multimodal treatment, appropriate monitoring is needed to identify and manage adverse events because of the different adverse effect profile for each analgesic medication or technique used.

• Specific components of effective multimodal care should be tailored to the patient, setting, and surgical procedure (strong recommendation; low-quality evidence).

• Multimodal treatment should include use of around-the-clock acetaminophen and/or NSAIDs for adults and children without contraindications (strong recommendation; high-quality evidence).

• For certain surgical sites, specific peripheral regional anesthetic techniques are effective and should be used in adults and children when appropriate (strong recommendation; high-quality evidence).

• For major thoracic and abdominal surgeries, neuraxial analgesia should be considered, especially in patients at risk for cardiac complications or prolonged ileus (strong recommendation; high-quality evidence).

• Other strong recommendations are supported by moderate-quality evidence.

• Oral opioids are preferred to IV opioids in patients who can tolerate oral administration, because the efficacy of IV is not superior to oral. Because postoperative pain is often continuous initially, it often requires around-the-clock dosing during the first 24 hours. Long-acting oral opioids are generally not recommended in the immediate postoperative period.

• Analgesics should not be administered intramuscularly because intramuscular administration can cause significant pain, absorption is unreliable, and it has no clearly shown advantages vs other routes of administration.
Patients requiring parenteral analgesia should be given IV PCA.

• Opioid-naive adults should not receive routine basal opioid infusion using IV PCA.

• Adults without contraindications may benefit from a preoperative dose of oral celecoxib.

• Gabapentin or pregabalin may be a suitable intervention in multimodal analgesia.

• Topical local analgesics combined with nerve blocks may be useful before circumcision.

• Intrapleural analgesia with local anesthetics is not recommended for pain control after thoracic surgery.

• When the need for analgesia is likely to be longer than a single injection can provide, continuous, local anesthetic-based peripheral regional analgesic techniques are recommended.

• Neuraxial administration of magnesium, benzodiazepines, neostigmine, tramadol, and ketamine is not recommended.
Numerous research gaps still exist, as indicated in the systematic review underlying these guidelines.

• Only 4 of 32 recommendations were supported by high-quality evidence, and 11 (regarding patient education, perioperative planning, patient evaluation, organizational structures and policies, and transitioning to outpatient care) were based on low-quality evidence.




CLINICAL IMPLICATIONS
• The APS has issued guidelines for postoperative pain management, recommending multimodal regimens tailored to the specific patient and procedure.

• Other strong recommendations for postoperative pain management were supported by moderate-quality evidence, including preference for oral to IV opioids when feasible and avoidance of intramuscular administration.

• Implications for the Healthcare Team: Members of the healthcare team should be aware that numerous research gaps still exist, and only 4 of 32 recommendations were supported by high-quality evidence.

CLICK HERE for more resources on Pain Management

WhatsApp No.: +2348055338879
Website Design Company in Lagos, Nigeria - CKDigital